Tivozanib (AV-951): Potent, Selective VEGFR Tyrosine Kinase Inhibitor for Oncology Research

Executive Summary: Tivozanib (AV-951) is a quinoline-urea derivative and second-generation tyrosine kinase inhibitor (TKI) with high specificity for VEGFR-1, VEGFR-2, and VEGFR-3, exhibiting an IC₅₀ of 160 pM for VEGFR-2 under in vitro conditions (Schwartz 2022). It demonstrates minimal off-target inhibition, including low c-KIT activity, and significant anti-angiogenic and antitumor effects in RCC models. Clinically, Tivozanib achieves a progression-free survival of 12.7 months in metastatic RCC, outperforming older VEGFR inhibitors under similar dosing regimens. APExBIO supplies Tivozanib (A2251) in a highly pure, research-ready format suitable for both in vitro and in vivo workflows (APExBIO product page).

Biological Rationale

Angiogenesis is essential for tumor growth and metastasis. The vascular endothelial growth factor (VEGF) signaling pathway, mediated by VEGFR-1, VEGFR-2, and VEGFR-3, regulates endothelial cell proliferation, migration, and new blood vessel formation (Schwartz 2022). Overexpression of VEGF ligands and receptors is a hallmark of many solid tumors, including renal cell carcinoma (RCC), ovarian, and colorectal cancers. Targeting VEGFRs with selective inhibitors is a validated strategy for suppressing tumor angiogenesis and progression. Resistance to earlier TKIs, often due to inadequate selectivity or off-target toxicity, underscored the need for second-generation agents with enhanced potency and safety.

Mechanism of Action of Tivozanib (AV-951)

Tivozanib is a highly selective, orally bioavailable pan-VEGFR inhibitor. It competitively binds to the ATP-binding site of VEGFR-1, VEGFR-2, and VEGFR-3, inhibiting their kinase activity. Its IC₅₀ against VEGFR-2 is 160 pM; for VEGFR-1 and VEGFR-3, inhibition is also in the subnanomolar range (Schwartz 2022). Tivozanib also inhibits phosphorylation of PDGFRβ and c-KIT at nanomolar concentrations in cellular assays, but with significantly lower potency compared to VEGFRs. This high selectivity reduces adverse events linked to off-target kinase blockade, distinguishing Tivozanib from multi-targeted TKIs like sunitinib or sorafenib. Inhibition of VEGFR signaling disrupts endothelial cell survival and angiogenic processes, resulting in reduced tumor vascularization and growth.

Evidence & Benchmarks

• Tivozanib inhibits VEGFR-2 activity with an IC₅₀ of 160 pM in cell-free kinase assays (Schwartz 2022, Table 4.1).
• In cellular models, Tivozanib blocks VEGFR autophosphorylation and downstream signaling at concentrations as low as 0.5 nM (Schwartz 2022, Fig. 3.6).
• Shows minimal off-target inhibition: c-KIT and PDGFRβ IC₅₀ values are >100-fold higher than for VEGFRs (Schwartz 2022, Table 4.1).
• In RCC xenograft models, Tivozanib induces >80% tumor growth inhibition at 1.5 mg/kg daily oral dosing (Schwartz 2022, Fig. 5.2).
• Phase III trials in metastatic RCC report a median progression-free survival of 12.7 months, superior to sunitinib under comparable conditions (Schwartz 2022, Clinical Data).
• Tivozanib demonstrates synergistic effects with EGFR inhibitors in ovarian carcinoma cell lines, enhancing apoptosis and growth inhibition at 10 μM, 48 h exposure (Schwartz 2022, Ch. 6).

For more on advanced strategies, see Tivozanib (AV-951): Advanced Strategies in VEGFR Inhibition; this article extends that review by integrating clinical and in vitro benchmarks under standardized protocols.

Applications, Limits & Misconceptions

Applications:

• Primary: Inhibition of angiogenesis in renal cell carcinoma, ovarian, and other solid tumor models.
• Research use: In vitro evaluation of VEGFR pathway blockade, tumor cell proliferation, and combinatorial screening with EGFR inhibitors.
• Clinical: Oral administration at 1.5 mg daily for 3 weeks on/1 week off cycles in RCC patients (Schwartz 2022).

Limits:

• Ineffective in tumor types lacking VEGF/VEGFR pathway dependence.
• Not indicated for hematological malignancies without angiogenic driver mutations.
• Limited activity in cases of acquired resistance due to alternative pro-angiogenic mechanisms.

For a precision methodology focus, see Tivozanib (AV-951): Precision VEGFR Inhibitor for Oncology Research; the present article adds comparative clinical efficacy data and clarifies dosing standards for translational workflows.

Common Pitfalls or Misconceptions

• Misconception: Tivozanib is a broad-spectrum TKI.
  Clarification: It is highly selective for VEGFRs, with minimal off-target kinase inhibition (Schwartz 2022).
• Misconception: Tivozanib is water-soluble.
  Clarification: It is insoluble in water; use DMSO (≥22.75 mg/mL) or ethanol (≥2.68 mg/mL with mild heat) for stock preparation (APExBIO).
• Misconception: All solid tumors respond equally to Tivozanib.
  Clarification: Efficacy is highest in VEGFR-driven models; tumors lacking VEGF dependence show limited response.
• Misconception: Long-term stock solutions are stable.
  Clarification: Solutions should not be stored long-term; prepare fresh before use and store solid at -20°C (APExBIO).

Workflow Integration & Parameters

Tivozanib (A2251) from APExBIO is supplied as a solid compound (MW 454.86, C₂₂H₁₉ClN₄O₅; chemical name: 1-[2-chloro-4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-3-(5-methyl-1,2-oxazol-3-yl)urea) for research use only (APExBIO product datasheet). Dissolve at ≥22.75 mg/mL in DMSO or ≥2.68 mg/mL in ethanol at room temperature with gentle warming. For in vitro experiments, a working concentration of 10 μM for 48 hours is standard for evaluating cell viability and apoptosis in cancer cell lines (Schwartz 2022). Solid compound should be stored at -20°C; avoid repeated freeze-thaw cycles. Solutions are best used immediately and should not be stored long-term.

For in vivo studies, Tivozanib is administered orally at 1.5 mg/kg daily in preclinical models. Clinical protocols recommend 1.5 mg orally once daily for 3 weeks, followed by 1 week off, in 4-week cycles for RCC patients. Monitor for known adverse effects, including hypertension and fatigue, which are typically milder than with less selective TKIs.

For additional workflow guidance, see Tivozanib (AV-951): Advancing VEGFR Signaling Research; this article updates those protocols by specifying optimal solvent conditions and clarifying solution stability for advanced in vitro designs.

Conclusion & Outlook

Tivozanib (AV-951) represents a transformative advance in anti-angiogenic cancer therapy and research. Its picomolar VEGFR-2 inhibition, high selectivity, and superior clinical performance in RCC set a new benchmark for VEGFR-targeted agents (Schwartz 2022). APExBIO's A2251 kit ensures consistent, high-purity compound for research applications. Future directions include further combinatorial studies with EGFR or immune checkpoint inhibitors, and mechanistic exploration in resistant tumor subtypes. Careful attention to workflow parameters and model selection will maximize translational impact in oncology.